We provide first-time evidence that the synovial endothelium-targeting peptide (SyETP) CKSTHDRLC successfully delivers conjugated IL4 to human rheumatoid synovium transplanted into SCID mice. SyETP, previously isolated by in vivo phage display and shown to preferentially localize to synovial xenografts, was linked by recombinant technology to hIL-4 via an MMPcleavable sequence. Both IL-4 and the MMP-cleavable sequence were shown to be functional.
Introduction
Rheumatoid arthritis (RA) is a systemic, inflammatory autoimmune disorder that presents as a symmetric arthritis associated with swelling and pain in multiple joints. Articular inflammation causes activation and proliferation of the synovial tissue with hypertrophy of the lining layer, expression of inflammatory cytokines, chemokine-mediated recruitment of inflammatory cells, as well as B cell activation with autoantibody production [1] [2] [3] . Cytokines such as interleukin (IL)-1, Tumour Necrosis Factor (TNF) and IL-6 are found in great abundance 4 . These cytokines mediate cartilage and bone degradation by augmenting matrix degrading enzymes such as aggrecanases and matrix metalloproteinases and the activation of osteoclasts, which cause, bone resorption.
Antagonists to these cytokines now play a fundamental role in the treatment of RA, most notably anti-TNF. These treatments result in clinical benefits for the majority of patients 3 , however, up to 30-40% of patients do not respond. In addition, due to systemic immunosuppression, there is a risk of reactivation of latent infections such as tuberculosis. There is a great need for the development of new targeted therapies, as they have the potential for diminishing systemic toxicity while increasing pharmacological drug concentrations at the disease site.
One therapeutic approach to decrease pro-inflammatory cytokine expression is to administer anti-inflammatory cytokines, several of which have been shown to be effective in models of RA [4] [5] [6] [7] [8] [9] [10] [11] . These include IFNβ 5 , IL-10 6 and IL-4, which has been shown to reduce cartilage destruction and inhibit neoangiogenesis 7, 8 as well as sharing some of the anti-inflammatory properties of IL-10 4, [9] [10] [11] . Clinical trials with IL-4 however reported a lack of efficacy, and it was speculated that to achieve an efficacious dose in the synovium, the administered dose would not be tolerated systemically. This cytokine pleiotropism is a limitation to their clinical use.
One approach to overcome these problems is to target the delivery of cytokine to the specific diseased tissue. Linking cytokines to targeting peptides or antibodies are progressing to clinical trials for the treatment of cancer [12] [13] [14] . However, this therapeutic modality in chronic inflammatory conditions such as RA has so far been relatively unexplored.
Neoangiogenesis in RA, similarly to cancer, leads to an enlarged vascular bed and leukocyte infiltration within the synovial tissues and ultimately accelerates disease progression 15 . These new vessels are discontinuous, leaky and present a dysregulated expression of a number of molecules such as integrins, cell surface proteoglycans, proteases, and extracellular matrix components as well as endothelial cell growth factor receptors which are virtually absent or barely detectable in established blood vessels 16 . The differences between these new vessels in RA and normal vessels provide a good opportunity for targeted therapy.
Neoangiogenesis is also observed when RA synovial tissue is transplanted into SCID mice. We have used this xenograft model for identification of tissue-specific synovial homing motifs 17 . This has been facilitated by the application of phage display of random peptides 18, 19 and antibody fragment libraries 20 to target microvasculature endothelium (MVE) in various tissues 21, 22 .
Homing peptide sequences have been generated for numerous organs in mice and human tumour vasculature 23, 24 and have been shown to target and concentrate drugs to tumours engrafted in nude mice 21, 23 . Notably, conjugation of the NGR homing peptide to TNF improved the 5 therapeutic index of TNF in preclinical studies 25 and NGR fused to human TNF is now entering Phase III clinical trials in cancer.
Treatment of mice with collagen-induced arthritis with RGD-containing cyclic peptide (RGD-4C), linked to a proapoptotic peptide dimer [D(KLAKLAK)2], decreased clinical arthritis and increased apoptosis of synovial blood vessels 26 . Recently, an unconjugated phage-encoded (CLDNQRPKC) peptide suppressed adjuvant-induced arthritis, attributed at least in part to peptide-mediated reduction of T-cell trafficking and the inhibition of angiogenesis 27, 28 . However, to our knowledge, there are no studies in the literature demonstrating specific targeting to human arthritic tissue. We have previously identified a synovial endothelium targeting 
IL-4 synergises with IL-1β to enhance IL-1ra production from synoviocytes in vitro.
To assess whether SyETP-linked IL-4 retained the capacity of activating anti-inflammatory pathways, primary RA-and OA-SF were stimulated with rIL-4 in the presence of the proinflammatory cytokine IL-1β (Supplementary Methods). Figure 2 shows that there was no constitutive expression of IL-1ra from resting synoviocytes isolated from patients with both RA and OA. Upon stimulation with IL-1β (10ng/ml), the concentration of IL-1ra in the culture supernatant was measured at 300pg/ml. Such IL-1ra induction was enhanced in a dose dependent fashion with increasing concentrations of rhIL-4 (5-50ng/ml) ranging from 1000-1500pg/ml. Importantly, rhIL-4 alone did not induce IL-1ra production. The synergistic effect of IL-4 and IL-1β on IL-1ra production was also observed for all three fusion proteins, albeit to a different degree. Importantly, however, there were no significant differences in the capability of the three fusion proteins to enhance IL-1ra production. In all cases, pre-incubation with IL-4 induced a highly significant (p<0.001) increase in the production of IL-1ra over IL-1β alone (Fig. 2) . This indicates that SyETP-linked IL-4 retained the capacity of stimulating the production of an anti-inflammatory cytokine in the presence of IL-1β.
The synovial specific peptide (CKSTHDRLC) retains targeting capability of fusion proteins to synovial grafts in vivo.
Having confirmed in vitro that the IL-4 in the constructs was bioactive and could activate antiinflammatory pathways, we next wanted to confirm that the SyETP in the fusion proteins had retained the synovial targeting capability in vivo. To assess this we radiolabeled the fusion proteins with 125 I and administered them intravenously into grafted SCID mice (Fig 3 a,b) . Prior to that experiment we confirmed that radiolabeling did not affect the integrity of the fusion proteins ( Supplementary Figure 1) . In vivo imaging by NanoSPECT-CT allowed quantification of the level of radioactivity in the grafts per mm Importantly, by exploiting the increased avidity of the triple peptide (IL-4-TP) the higher activity could be extended to 180 minutes, peaking between 90-120 minutes post-injection. In contrast, the scrambled IL-4-TS showed no enhanced retention by the synovial graft and dissipated from both synovial and skin xenografts at the same rate. These data confirm that SyETP (CKSTHDRLC) leads to preferential accumulation of fusion proteins in synovial compared to control skin grafts. Fig.4 b,c] . The same pattern was observed in the nuclear fractions (data not shown).
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Discussion
In this study we have demonstrated that recombinant fusion proteins containing one or three copies of a SyETP can target and retain IL-4 in synovial tissue grafts and that the length of time the fusion proteins are retained increases with increased copies of the peptide. In addition, we have shown that the conjugated rIL-4 is delivered in a bioactive form in vivo. These experiments were preceded by in vitro confirmation that IL-4 in the fusion proteins was bioactive and the MMP cleavage site accessible and susceptible to cleavage with MMP1. In vitro the fusion proteins were shown to have approximately equal IL-4 bioactivity both pre-and post-cleavage with MMP1. We were also able to demonstrate the capacity of these constructs to exert antiinflammatory activity by measuring the induction of an anti-inflammatory mediator: IL-1ra.
It is well know that in RA, pro-and anti-inflammatory cytokine networks are operational both at local and systemic levels and that IL-1β and TNF are pivotal for the development of chronicity and tissue damage 33, 34 . The physiological activity of IL-1 is controlled by its naturally occurring inhibitor, IL-1ra which binds to IL-1 receptors without activating the target cell. It is thought that dysregulation of IL-1ra may be responsible for the predominance of IL-1 in RA 35 . The main source of IL-1ra in the joint are synovial macrophages, although RA synovial fibroblasts (RASF) also produce it. Both cell types are known to contribute significantly to the perpetuation of disease 36, 37 . Notably, IL-4 has been shown to reduce IL-1β production by increasing IL-1Ra in these cells 38, 39 . In our study we have shown that IL-4 augments secretion of IL-1ra by RASF in the presence of IL-1β in vitro both alone and when conjugated to SyETP thereby validating the capacity of our constructs to deliver powerful anti-inflammatory signals.
Importantly, these in vitro experiments provided the evidence to support the rationale for testing the therapeutic properties of the constructs in vivo, on the premise that, if SyETP conjugation delivers IL-4 preferentially to synovial tissue, this would increase the therapeutic index of the cytokine as has been shown for TNF when conjugated to the tumour neovasculature by the homing peptide NGR in a pre-clinical model 25 . Clinical use of TNF has been limited due to systemic toxicity 40 , however NGR-humanTNF is now entering Phase III clinical trials as a systemic agent [http://clinicaltrials.gov, trial identifier NCT01098266]. In the case of inflammatory disease, targeting has proved effective in animal models such as collagen-induced arthritis, where the effects of IL-10 on paw swelling were significantly enhanced when coupled to an antibody designed to target inflamed joints 41, 42 . However to our knowledge few studies have explored the concept of targeted therapy in human RA.
Our fusion proteins have half lives in the range of 30-60 minutes (Supplementary Methods and
data not shown), comparable to that of free IL-4 (12-19 mins 43, 44 ). Targeting extends retention specifically in the target tissue and we reason that non-retained protein would be quickly cleared from the circulation, reducing the potential for unwanted systemic effects.
Previously, it has been problematic to isolate targeting peptides that bind their ligands with high affinity. The results of this study confirm that it is possible to use multiples of cyclic peptides to enhance binding avidity and increase the period of retention in the microvasculature of synovial tissue. Identifying the molecule that binds to the target peptide will be important in order to further develop other targeting moieties and also to improve our understanding at the molecular level of what makes the synovial microvasculature different from that at other tissues or organs.
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Of extreme relevance and importance is the confirmation in this paper of the capacity of the 
Construction of fusion proteins
Human IL-4 (hIL-4) cDNA was amplified by PCR (from a plasmid kindly provided by DNAX Corp, USA), using the primers CCCAAGCTTATGGGTCTCACCTCCCAACTGC and ATCTTTTCAGGAATTCGCTCGAACACTTTGAATATTTCTCTC to add HindIII and EcoRI sites to the 5' and 3' ends respectively. After digestion with HindIII and partial digestion with EcoRI due to an endogenous EcoRI site, DNA of the appropriate size was purified by gel extraction and inserted into a pcDNA3 vector encoding an MMP-cleavable site 25 flanked by EcoRI and NotI restriction sites. Novel DNA sequences encoding one or three copies of a synovial homing peptide 22 and a C-terminal His-tag followed by an ApaI restriction site were NanoSPECT-CT animal scanner (Bioscan Inc.Washington DC, USA) as previously described 46 .
The animals were kept warm and were anaesthetised using 2% isoflurane for the duration of the scan. Helical SPECT images of the transplants were acquired in 20 projections over 30 minutes using the 4-headed camera with 4 x 9 (1.4mm) pinhole collimators. CT images were acquired in 180 projections and 1000ms exposure time using a 45kVP X-ray source over 3 minutes.
Radionuclide images were reconstructed using HiSPECT (Scivis GmbH) iterative reconstruction software and fused with CT images using proprietary InVivoScope (Bioscan) software. A three dimensional volume-of-interest was defined around each graft to calculate the volume and level of activity (MBq) within. Uptake was expressed as activity (MBq) per mm 3 tissue. Equipment and methodology used have been previously validated in this model 46 .
Detection of pSTAT6 in human tissue
